F-group (family)
214.1.1.1 SH2
Ligands and drugs
2,064
Member domains
501
with ligand contacts (≤ 4 Å)
24.3% of members
467
with DrugDomain annotations
22.6% of members
245
with a DrugBank compound
11.9% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 214.1.1.1 belongs to X-group 214 SH2, which binds 8.1 ligand superclasses per 20 proteins, broader than 60% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB12010 | — | Fostamatinib | 19 |
| DB15035 | — | — | 8 |
| DB02175 | MLA | Malonic acid | 7 |
| DB08357 | P4G | Diethylene glycol diethyl ether | 4 |
| DB19137 | VKS | Batoprotafib | 4 |
| DB01962 | PTR | Phosphonotyrosine | 3 |
| DB09079 | — | Nintedanib | 3 |
| DB01133 | — | — | 2 |
| DB01830 | CC1 | AP-22408 | 2 |
| DB02010 | STU | Staurosporine | 2 |
| DB06486 | — | — | 2 |
| DB08059 | — | Wortmannin | 2 |
| DB08896 | — | — | 2 |
| DB16656 | — | — | 2 |
| DB00936 | SAL | Salicylic acid | 1 |
| DB01254 | — | Dasatinib | 1 |
| DB01678 | 687 | RU84687 | 1 |
| DB01773 | UR2 | 4-[3-carboxymethyl-3-(4-phosphonooxy-benzyl)-ureido]-4-[(3-cyclohexyl-propyl)-methyl-carbamoyl]butyric acid | 1 |
| DB01866 | 256 | RU79256 | 1 |
| DB01908 | 493 | RU85493 | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 29 |
| 5OD | 6-(4-azanyl-4-methyl-piperidin-1-yl)-3-[2,3-bis(chloranyl)phenyl]pyrazin-2-amine | 28 |
| NAmetal | SODIUM ION | 21 |
| C78 | [1-[1-(6-CARBAMOYL-CYCLOHEX-2-ENYLCARBAMOYL)-CYCLOHEXYLCARBAMOYL]-2-(4-PHOSPHONOOXY-PHENYL)- ETHYL]-CARBAMIC ACID 3-AMINOBENZYLESTER | 12 |
| 83Q | 6-[4-(aminomethyl)-4-methyl-piperidin-1-yl]-3-[2,3-bis(chloranyl)phenyl]sulfanyl-pyrazin-2-amine | 8 |
| MLA | MALONIC ACID | 7 |
| S1S | 2-(4-((9S,10S,14S,Z)-18-(2-AMINO-2-OXOETHYL)-9-(CARBOXYMETHYL)-14-(NAPHTHALEN-1-YLMETHYL)-8,17,20-TRIOXO-7,16,19-TRIAZASPIRO[5.14]ICOS-11-EN-10-YL)PHENYL)MALONIC ACID | 6 |
| SCN | THIOCYANATE ION | 6 |
| UNX | UNKNOWN ATOM OR ION | 6 |
| ZLY | (4-{(10R,11E,14S,18S)-18-(2-amino-2-oxoethyl)-14-[(naphthalen-1-yl)methyl]-8,17,20-trioxo-7,16,19-triazaspiro[5.14]icos-11-en-10-yl}phenyl)acetic acid | 6 |
| JH9 | [4-[(2~{S})-3-[(4-fluoranyl-3-prop-2-enyl-phenyl)methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate | 5 |
| A1H4K | 7-azanyl-N-pyridin-3-yl-3H-pyrrolo[3,2-b]pyridine-2-carboxamide | 4 |
| DYV | 1-(3-chloro-4-{[1-(2-hydroxy-3-methoxyphenyl)-5-oxo[1,2,4]triazolo[4,3-a]quinazolin-4(5H)-yl]methyl}benzene-1-carbonyl)-L-proline | 4 |
| DZS | 3-{4-[(2-chlorophenyl)methyl]-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-a]quinazolin-1-yl}-4-hydroxybenzoic acid | 4 |
| DZV | 4-[(2-chlorophenyl)methyl]-1-(2-hydroxy-3-methoxyphenyl)[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one | 4 |
| FIZ | 2-[(3S,4R)-4-azanyl-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-[2,3-bis(chloranyl)phenyl]-3-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-one | 4 |
| JE1 | 2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-{[2-(trifluoromethyl)pyridin-3-yl]sulfanyl}pyrimidin-4(3H)-one | 4 |
| JEA | 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-[3-chloro-2-(cyclopropylamino)pyridin-4-yl]-5-methyl-2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one | 4 |
| JIH | [4-[(2~{S})-3-[[3-(2-chloranylethanoylamino)phenyl]methylamino]-2-[2-(4-fluorophenyl)ethanoylamino]-3-oxidanylidene-propyl]phenyl] dihydrogen phosphate | 4 |
| KID | 2-[4-(aminomethyl)-4-methyl-piperidin-1-yl]-5-[2,3-bis(chloranyl)phenyl]-3-methyl-pyrrolo[2,1-f][1,2,4]triazin-4-one | 4 |